Assessing Savara (SVRA) Valuation After Accelerated Review Progress For MOLBREEVI

Regulatory milestones in focus for Savara stock

Savara (SVRA) is back on investors’ radar after the U.K. regulator accepted the Marketing Authorisation Application for MOLBREEVI under Accelerated Review, alongside ongoing priority reviews in the U.S. and Europe.

See our latest analysis for Savara.

The recent string of regulatory updates appears to be feeding into share price momentum, with a 1-month share price return of 9.68% and a 1-year total shareholder return of 122.31% from a last close of US$5.78. This suggests interest has been building rather than fading.

If progress on rare disease treatments has caught your attention, it can be worth widening the lens and checking out 37 healthcare AI stocks.

With Savara still loss making, carrying a market value of about US$1.4b and trading well below the current analyst price target, investors now need to ask whether there is genuine upside here or if future growth is already priced in.

Preferred price to book of 7.2x: Is it justified?

Savara trades on a P/B of 7.2x, which sits well below the peer average of 19.4x but above the broader US biotechs industry at 2.2x.

P/B compares the company’s market value to its net assets, which can be a useful yardstick for development stage biotechs that have limited or no revenue and are still loss making. In this case, Savara’s P/B suggests investors are placing a meaningful value on its rare respiratory disease pipeline and future earnings potential rather than current financials.

Against direct peers, the 7.2x multiple appears restrained, which may indicate the market is not assigning the same premium as it does to some other rare disease names. Against the wider industry, however, the same 7.2x figure looks expensive relative to the 2.2x average, which indicates investors are still willing to pay a premium compared to the typical biotech.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 7.2x (ABOUT RIGHT)

However, there are clear pressure points, including ongoing losses of US$118.837m and dependence on successful late stage trials and regulatory outcomes for a single lead asset.

Find out about the key risks to this Savara narrative.

Next Steps

With mixed signals on valuation and execution risk, the real question is how you weigh them for your own portfolio. Move quickly from headline impressions to the underlying data and test your thesis against the 1 key reward and 2 important warning signs

Ready for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that might fit your style even better, so broaden your watchlist now using the Simply Wall Street Screener.

• Zero in on potential mispricings by checking out 61 high quality undervalued stocks that pair quality fundamentals with attractive valuations.
• Build a steadier income stream by reviewing 13 dividend fortresses that focus on higher yielding payouts with defensive characteristics.
• Prioritise balance sheet strength by scanning solid balance sheet and fundamentals stocks screener (40 results) to see which companies combine financial resilience with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com